在接受不同犬内脏莱什曼病治疗方案的狗中抗体动态
Eliesse Pereira Costa1, Gisele Vaz Aguirre Samoel1, Gilneia da Rosa1
1Programa de Pós-graduação em Medicina Veterinária, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.
概括
这项研究追踪了治疗后患有犬内脏雷什曼病 (CVL) 的狗的抗体水平. 结合疗法,包括疫苗,减少复发和稳定抗体标位,表明CVL犬的免疫反应得到改善.
科学领域:
- 兽医免疫学 兽医免疫学
- 寄生虫学的寄生虫学
- 传染性疾病 传染性疾病
背景情况:
- 狗内脏莱什曼病 (CVL) 是一种由莱什曼病寄生虫引起的重大动物性疾病.
- 对狗的CVL有效的治疗和监测策略对于公共卫生至关重要.
- 治疗犬的抗体动态和临床结果需要进一步调查.
研究的目的:
- 评估不同治疗方案对CVL犬的抗体动态的影响.
- 在一年的时间内评估治疗犬的临床分数和复发率.
- 了解治疗,免疫反应和犬类莱什曼病的疾病进展之间的关系.
主要方法:
- 一组由21只自然感染的狗组成的队列被分为三个治疗组.
- 第1组接受了阿洛普林醇;第2组接受了阿洛普林醇和米尔特福辛;第3组接受了阿洛普林醇,米尔特福辛和莱什-Tec®疫苗.
- 血清抗体标位每月通过间接免疫光测量,并进行临床评估.
主要成果:
- 与治疗前相比,所有治疗组的临床症状均有所改善.
- 接受单独Allopurinol或与Miltefosine的狗具有较低的抗体标位和临床评分,但经历了复发.
- 接种阿洛普林醇,米尔特福辛和疫苗的组显示抗体标位稳定,没有临床复发.
结论:
- 组合疗法,特别是使用Leish-Tec®疫苗,通过稳定抗体标位和预防复发,在治疗CVL方面显得有效.
- 临床和治疗监测必须通过免疫反应评估来补充.
- 需要进一步的研究,以充分了解治疗狗的传播风险.
更多相关视频
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
22.3K
08:17Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major
Published on: October 28, 2022
1.4K
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...